Anifrolumab

Drug Profile

Anifrolumab

Alternative Names: Anti-IFNaR MAb - Bristol-Myers Squibb/MedImmune; MDX-1333; MEDI-546

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex
  • Developer Medarex; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon alpha beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • No development reported Scleroderma

Most Recent Events

  • 14 Jun 2017 Adverse events, efficacy, immunogenicity data from a phase I trial in Healthy volunteers presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 21 Feb 2017 Medimmune and Astrazenca completes a phase II trial in Systemic lupus erythematosus in Japan (IV) (NCT01559090)
  • 14 Feb 2017 Phase-II clinical trials in Systemic lupus erythematosus in USA, Hungary, South Korea (SC) (NCT02962960)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top